MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women
Biomedicines,
Год журнала:
2025,
Номер
13(4), С. 855 - 855
Опубликована: Апрель 2, 2025
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
is
the
most
common
chronic
influenced
by
genetic,
lifestyle,
and
environmental
factors.
While
MASLD
more
prevalent
in
men,
women
are
at
increased
risk
after
menopause,
highlighting
critical
pathogenetic
role
of
sex
hormones.
The
complex
interplay
between
estrogen
deficiency,
visceral
fat
accumulation,
metabolic
syndrome
(MetS),
inflammation
accelerates
progression,
increases
cardiovascular
(CV)
risk,
triggers
a
cycle
worsening
adiposity,
dysfunction,
psychological
problems,
including
eating
disorders.
Weight
loss
postmenopausal
can
significantly
improve
both
outcomes,
helping
to
prevent
related
conditions.
This
review
examines
prevalence
MASLD,
its
comorbidities
(type
2
diabetes
T2D,
CV,
mental
disorders),
mechanisms,
pharmacological
treatment
with
GLP-1
receptor
agonists
(GLP1-RAs),
focus
on
women.
Given
use
GLP1-RAs
obesity
T2D
patients,
increase
MetS
this
analyzes
potential
stable
GLP-1–estrogen
conjugate
as
therapeutic
approach
subgroup.
By
combining
synergistic
effects
hormones,
dual
agonist
has
been
shown
food
intake
reward
suppression,
resulting
greater
weight
improved
insulin
sensitivity,
glucose,
lipid
metabolism.
Therefore,
we
hypothesize
that
pharmacotherapy
may
provide
targeted
benefits
than
either
hormone
alone
protecting
liver,
β-cells,
overall
health.
As
these
only
supported
preclinical
data,
highlights
need
for
future
research
evaluate
confirm
mechanisms
efficacy
clinical
settings,
particularly
Язык: Английский
The association between liver fibrosis score and incident dementia: A nationwide retrospective cohort study
Alzheimer s & Dementia,
Год журнала:
2024,
Номер
20(8), С. 5385 - 5397
Опубликована: Июль 1, 2024
Abstract
BACKGROUND
We
assessed
the
relationship
of
liver
fibrosis
score
with
incident
dementia
in
a
large,
national
sample.
METHODS
For
this
retrospective
cohort
study,
data
dementia‐free
individuals
aged
40‐69
years
were
derived
from
electronic
records
largest
healthcare
provider
Israel.
The
association
between
(FIB‐4),
routine
laboratory
measurements,
and
was
explored
through
multivariate
cox
regression
models.
RESULTS
Of
total
sample
(
N
=
826,578,
mean
age
55
±
8
at
baseline),
636,967
(77%)
had
no
fibrosis,
180,114
(21.8%)
inconclusive
status
9497
(1.2%)
high
risk
for
advanced
fibrosis.
Over
median
follow‐up
17
years,
41,089
cases
recorded.
Inconclusive
associated
increased
(HR
1.09,
95%CI:
1.07–1.11
HR
1.18,
1.10–1.27,
respectively).
This
remained
robust
seven
sensitivity
analyses.
CONCLUSIONS
Liver
serum‐based
algorithm
may
serve
as
factor
general
population.
Highlights
predict
diagnosis
9%
risk.
Advanced
18%
Findings
analyses
after
adjustments.
Язык: Английский